Latest filing published 18 Mar 2026 for Allogene Therapeutics, Inc., €103k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
David D. Chang (chief executive) discloses dealings in Allogene Therapeutics, Inc. to SEC (Form 4). The record holds 12 filings, for trades running from 24 May 2021 to 16 March 2026.
Sales make up the whole of the open-market record (5 sales, €573k). Besides market trades, the filings include 6 share grants and 1 option exercise. Since January 2026: no purchases and 2 sales on the market.
On 18 March 2026 came the latest disclosure, an open-market sale for €103k in Allogene Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations